Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs
Executive Summary
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
You may also be interested in...
Pharma Finds Its Way in AI
Early adopters of artificial intelligence are discovering how best to use it. Some of them are sharing lessons they have learned.
Alvogen Strikes Deals For Pfenex’ Teriparatide
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.